Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices.


Journal

European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966

Informations de publication

Date de publication:
01 04 2022
Historique:
pubmed: 12 1 2022
medline: 6 4 2022
entrez: 11 1 2022
Statut: ppublish

Résumé

Assessment of disability-adjusted life years (DALYs) resulting from non-communicable diseases (NCDs) requires specific calculation methods and input data. The aims of this study were to (i) identify existing NCD burden of disease (BoD) activities in Europe; (ii) collate information on data sources for mortality and morbidity; and (iii) provide an overview of NCD-specific methods for calculating NCD DALYs. NCD BoD studies were systematically searched in international electronic literature databases and in grey literature. We included all BoD studies that used the DALY metric to quantify the health impact of one or more NCDs in countries belonging to the European Region. A total of 163 BoD studies were retained: 96 (59%) were single-country or sub-national studies and 67 (41%) considered more than one country. Of the single-country studies, 29 (30%) consisted of secondary analyses using existing Global Burden of Disease (GBD) results. Mortality data were mainly derived (49%) from vital statistics. Morbidity data were frequently (40%) drawn from routine administrative and survey datasets, including disease registries and hospital discharge databases. The majority (60%) of national BoD studies reported mortality corrections. Multimorbidity adjustments were performed in 18% of national BoD studies. The number of national NCD BoD assessments across Europe increased over time, driven by an increase in BoD studies that consisted of secondary data analysis of GBD study findings. Ambiguity in reporting the use of NCD-specific BoD methods underlines the need for reporting guidelines of BoD studies to enhance the transparency of NCD BoD estimates across Europe.

Sections du résumé

BACKGROUND
Assessment of disability-adjusted life years (DALYs) resulting from non-communicable diseases (NCDs) requires specific calculation methods and input data. The aims of this study were to (i) identify existing NCD burden of disease (BoD) activities in Europe; (ii) collate information on data sources for mortality and morbidity; and (iii) provide an overview of NCD-specific methods for calculating NCD DALYs.
METHODS
NCD BoD studies were systematically searched in international electronic literature databases and in grey literature. We included all BoD studies that used the DALY metric to quantify the health impact of one or more NCDs in countries belonging to the European Region.
RESULTS
A total of 163 BoD studies were retained: 96 (59%) were single-country or sub-national studies and 67 (41%) considered more than one country. Of the single-country studies, 29 (30%) consisted of secondary analyses using existing Global Burden of Disease (GBD) results. Mortality data were mainly derived (49%) from vital statistics. Morbidity data were frequently (40%) drawn from routine administrative and survey datasets, including disease registries and hospital discharge databases. The majority (60%) of national BoD studies reported mortality corrections. Multimorbidity adjustments were performed in 18% of national BoD studies.
CONCLUSION
The number of national NCD BoD assessments across Europe increased over time, driven by an increase in BoD studies that consisted of secondary data analysis of GBD study findings. Ambiguity in reporting the use of NCD-specific BoD methods underlines the need for reporting guidelines of BoD studies to enhance the transparency of NCD BoD estimates across Europe.

Identifiants

pubmed: 35015851
pii: 6500281
doi: 10.1093/eurpub/ckab218
pmc: PMC8975530
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-296

Investigateurs

Balázs Ádám (B)
Ala'a Alkerwi (A)
Boris Bikbov (B)
Anette Kocbach Bølling (AK)
Susanne Breitner (S)
Sarah Cuschieri (S)
Christina C Dahm (CC)
Terje Andreas Eikemo (TA)
Florian Fischer (F)
Alberto Freitas (A)
Juan Manuel García-González (JM)
Federica Gazzelloni (F)
Mika Gissler (M)
Brigita Hengl (B)
Paul Hynds (P)
Gaetano Isola (G)
Lea S Jakobsen (LS)
Zubair Kabir (Z)
Ann Kristin Knudsen (AK)
Naime Meriç Konar (NM)
Carina Ladeira (C)
Aaron Liew (A)
Marjeta Majer (M)
Enkeleint A Mechili (EA)
Vildan Mevsim (V)
Milena Santric Milicevic (MS)
Louise Mitchell (L)
Lorenzo Monasta (L)
Stefania Mondello (S)
Evangelia Nena (E)
Edmond S W Ng (ESW)
Vikram Niranjan (V)
Rónán O'Caoimh (R)
Mark Ryan O'Donovan (MR)
Alberto Ortiz (A)
Elena Pallari (E)
Panagiotis Petrou (P)
Miguel Reina Ortiz (MR)
Silvia Riva (S)
Hanène Samouda (H)
João V Santos (JV)
Cornelia Melinda Adi Santoso (CM)
Tugce Schmitt (T)
Dimitrios Skempes (D)
Ana Catarina Sousa (AC)
Aleksandar Stevanovic (A)
Gerhard Sulo Natasa Terzic (GSN)
Zorica Terzic-Supic (Z)
Jovana Todorovic (J)
Fimka Tozija (F)
Brigid Unim (B)
Lisa Van Wilder (L)
Orsolya Varga (O)
Francesco S Violante (FS)
Grant M A Wyper (GMA)

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association.

Références

Arch Public Health. 2020 Dec 31;78(1):137
pubmed: 33384020
Arch Public Health. 2016 Aug 22;74:37
pubmed: 27551405
Lancet Oncol. 2019 Nov;20(11):1493-1505
pubmed: 31521509
Popul Health Metr. 2012 Sep 12;10(1):19
pubmed: 22967055
PLoS One. 2018 May 30;13(5):e0197047
pubmed: 29847573
Eur J Public Health. 2020 Feb 1;30(1):2-3
pubmed: 31978226
Eur J Cancer. 2008 Jul;44(10):1345-89
pubmed: 18280139
Open Med. 2009;3(3):e123-30
pubmed: 21603045
Eur J Public Health. 2018 Aug 1;28(4):773-778
pubmed: 29697771
Bull World Health Organ. 1994;72(3):429-45
pubmed: 8062401
J Health Econ. 1997 Dec;16(6):703-30
pubmed: 10176780
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Ecancermedicalscience. 2016 May 12;10:641
pubmed: 27350787

Auteurs

Periklis Charalampous (P)

Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Vanessa Gorasso (V)

Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Dietrich Plass (D)

Department for Exposure Assessment and Environmental Health Indicators, German Environment Agency, Berlin, Germany.

Sara M Pires (SM)

National Food Institute, Technical University of Denmark, Lyngby, Denmark.

Elena von der Lippe (E)

Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany.

Alibek Mereke (A)

Al-Farabi Kazakh National University, Almaty, Kazakhstan.

Jane Idavain (J)

National Institute for Health Development, Tallinn, Estonia.

Katarzyna Kissimova-Skarbek (K)

Department of Health Economics and Social Security, Jagiellonian University Medical College, Krakow, Poland.

Joana Nazaré Morgado (JN)

Environmental Health and Nutrition Laboratory, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.

Che Henry Ngwa (CH)

School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Isabel Noguer (I)

Carlos III Institute of Health, National School of Public Health, Madrid, Spain.

Alicia Padron-Monedero (A)

Carlos III Institute of Health, National School of Public Health, Madrid, Spain.

María José Santi-Cano (MJ)

Research Group on Nutrition: Molecular, pathophysiological and social issues, Biomedical Research and Innovation Institute of Cádiz (INiBICA), University of Cádiz, Cádiz, Spain.

Rodrigo Sarmiento (R)

Carlos III Institute of Health, National School of Public Health, Madrid, Spain.
Medicine School, University of Applied and Environmental Sciences, Bogota, Colombia.

Brecht Devleesschauwer (B)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium.

Juanita A Haagsma (JA)

Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH